menu
    • menu
    [{"orgOrder":0,"company":"Fosun Pharmaceutical","sponsor":"GHIT Fund","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2023","type":"Financing","leadProduct":"Artemether","moa":"||Ferriprotoporphyrin IX","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Fosun Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fosun Pharmaceutical \/ GHIT Fund","highestDevelopmentStatusID":"10","companyTruncated":"Fosun Pharmaceutical \/ GHIT Fund"}]

    Find Clinical Drug Pipeline Developments & Deals for Amodiaquine

    Menu

    Amodiaquine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fosun Pharmaceutical

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            Fosun Pharmaceutical

                            China arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Artemether,Amodiaquine,Lumefantrine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase III

                            Sponsor : GHIT Fund

                            Deal Size : $3.3 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for a New Antimalarial Drug Receives 500 M...

                            Details : The financing will be used for a clinical phase III trial for a fixed-dose combination of artemether-lumefantrine-amodiaquine drug (three existing antimalarial drugs already developed, marketed and sold) against malaria.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 13, 2023

                            Lead Product(s) : Artemether,Amodiaquine,Lumefantrine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase III

                            Sponsor : GHIT Fund

                            Deal Size : $3.3 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth